HYPE 201404534 R 3 Online Supplement for Long-Term Reduction of High Blood Pressure by Angiotensin II DNA Vaccine in Spontaneously Hypertensive Rats

[1]  Yijia Chen,et al.  Vaccines in the management of hypertension , 2010, Expert opinion on biological therapy.

[2]  M. Raizada,et al.  New Cardiovascular and Pulmonary Therapeutic Strategies Based on the Angiotensin-Converting Enzyme 2/Angiotensin-(1–7)/Mas Receptor Axis , 2012, International journal of hypertension.

[3]  R. Edelman,et al.  Phase I Trial of an Alhydrogel Adjuvanted Hepatitis B Core Virus-Like Particle Containing Epitopes of Plasmodium falciparum Circumsporozoite Protein , 2008, PloS one.

[4]  K. Tamai,et al.  In vivo gene introduction into keratinocytes using jet injection , 1999, Gene Therapy.

[5]  Shixia Wang,et al.  Novel DNA vaccine based on hepatitis B virus core gene induces specific immune responses in Balb/c mice. , 2005, World journal of gastroenterology.

[6]  David A. Anderson,et al.  Virus-like particles: Passport to immune recognition , 2006, Methods.

[7]  D. Weiner,et al.  DNA vaccination: antigen presentation and the induction of immunity , 2000, Journal of leukocyte biology.

[8]  J. Mascola,et al.  A West Nile virus DNA vaccine utilizing a modified promoter induces neutralizing antibody in younger and older healthy adults in a phase I clinical trial. , 2011, The Journal of infectious diseases.

[9]  R. Zinkernagel,et al.  T cell-independent type I antibody response against B cell epitopes expressed repetitively on recombinant virus particles. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[10]  J. Ménard,et al.  Active immunization against renin in normotensive marmoset. , 1987, Proceedings of the National Academy of Sciences of the United States of America.

[11]  Morris J. Brown,et al.  Randomized double-blind placebo-controlled study of an angiotensin immunotherapeutic vaccine ( PMD 3117 ) in hypertensive subjects , 2004 .

[12]  Ashley J. Birkett,et al.  Phase I Testing of a Malaria Vaccine Composed of Hepatitis B Virus Core Particles Expressing Plasmodium falciparum Circumsporozoite Epitopes , 2004, Infection and Immunity.

[13]  A. Wald,et al.  Phase I Study of a Herpes Simplex Virus Type 2 (HSV-2) DNA Vaccine Administered to Healthy, HSV-2-Seronegative Adults by a Needle-Free Injection System , 2008, Clinical and Vaccine Immunology.

[14]  B. Dubois,et al.  Subacute meningoencephalitis in a subset of patients with AD after Aβ42 immunization , 2003, Neurology.

[15]  Y. Liao,et al.  Target organ protection from a novel angiotensin II receptor (AT1) vaccine ATR12181 in spontaneously hypertensive rats. , 2006, Cellular & molecular immunology.

[16]  K. Tsuchiya,et al.  Aldosterone antagonist facilitates the cardioprotective effects of angiotensin receptor blockers in hypertensive rats , 2004, Journal of hypertension.

[17]  Larry R. Smith,et al.  A novel therapeutic cytomegalovirus DNA vaccine in allogeneic haemopoietic stem-cell transplantation: a randomised, double-blind, placebo-controlled, phase 2 trial. , 2012, The Lancet. Infectious diseases.

[18]  M. Bachmann,et al.  Vaccines against non-communicable diseases. , 2010, Current opinion in immunology.

[19]  H. Volk,et al.  A vaccine for hypertension based on virus-like particles: preclinical efficacy and phase I safety and immunogenicity , 2007, Journal of hypertension.

[20]  G. Remuzzi,et al.  Disruption of the Ang II type 1 receptor promotes longevity in mice. , 2009, The Journal of clinical investigation.

[21]  H. Volk,et al.  Effect of immunisation against angiotensin II with CYT006-AngQb on ambulatory blood pressure: a double-blind, randomised, placebo-controlled phase IIa study , 2008, The Lancet.

[22]  P. Pumpens,et al.  HBV Core Particles as a Carrier for B Cell/T Cell Epitopes , 2001, Intervirology.

[23]  P. Kremsner,et al.  Safety and Enhanced Immunogenicity of a Hepatitis B Core Particle Plasmodium falciparum Malaria Vaccine Formulated in Adjuvant Montanide ISA 720 in a Phase I Trial , 2005, Infection and Immunity.

[24]  D. Schenk.  Amyloid-beta immunotherapy for Alzheimer's disease: the end of the beginning. , 2002, Nature reviews. Neuroscience.